LeMaitre Vascular (NASDAQ:LMAT) Releases Q4 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its fourth quarter 2026 earnings guidance on Tuesday. The company provided EPS guidance of 0.750-0.81 for the period, compared to the consensus earnings per share estimate of 0.790. The company issued revenue guidance of $71.1 million-$73.1 million. LeMaitre Vascular also updated its FY 2026 guidance to 2.840-2.940 EPS.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on LMAT shares. Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, June 30th. Citizens Jmp boosted their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research report on Wednesday, May 6th. Zacks Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Barrington Research reiterated an “outperform” rating and issued a $120.00 price target on shares of LeMaitre Vascular in a report on Wednesday, June 3rd. Finally, Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $112.60.

LeMaitre Vascular Stock Up 2.1%

LMAT traded up $2.17 during trading on Tuesday, hitting $105.78. The stock had a trading volume of 405,320 shares, compared to its average volume of 255,427. The stock has a 50 day simple moving average of $97.27 and a two-hundred day simple moving average of $99.90. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. LeMaitre Vascular has a twelve month low of $79.39 and a twelve month high of $118.01. The company has a market capitalization of $2.42 billion, a PE ratio of 39.03, a PEG ratio of 2.81 and a beta of 0.52.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). The business had revenue of $70.38 million for the quarter, compared to analyst estimates of $71.47 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The business’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.60 earnings per share. On average, research analysts predict that LeMaitre Vascular will post 3 earnings per share for the current year.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,881 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the completion of the sale, the chief executive officer owned 1,430,019 shares of the company’s stock, valued at approximately $155,428,765.11. This trade represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bridget A. Ross sold 5,044 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $111.10, for a total value of $560,388.40. Following the completion of the transaction, the director owned 3,942 shares of the company’s stock, valued at $437,956.20. This trade represents a 56.13% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 54,453 shares of company stock valued at $5,906,174. 7.40% of the stock is currently owned by corporate insiders.

LeMaitre Vascular News Summary

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Second-quarter revenue rose 9.6% year over year to $70.38 million, while EPS increased from $0.60 to $0.74. The company also reported a healthy 24.35% net margin and announced a quarterly dividend of $0.25 per share. LeMaitre Q2 2026 Financial Results
• Neutral Sentiment: Management projected fourth-quarter 2026 EPS of $0.75–$0.81, broadly around the $0.79 analyst consensus, suggesting some potential for results to meet expectations later in the year.
• Negative Sentiment: Second-quarter EPS of $0.74 missed the $0.81 consensus estimate, and revenue of $70.38 million came in below the $71.47 million forecast. LeMaitre Vascular Earnings Results
• Negative Sentiment: Full-year 2026 guidance was reduced to EPS of $2.84–$2.94 and revenue of $274.3 million–$278.3 million, below consensus estimates of $3.00 EPS and $279.9 million revenue.
• Negative Sentiment: Third-quarter guidance also trailed expectations, with EPS of $0.66–$0.71 versus $0.73 consensus and revenue of $66.3 million–$68.3 million versus $69.0 million expected.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC acquired a new stake in LeMaitre Vascular during the second quarter worth about $47,000. Geneos Wealth Management Inc. increased its holdings in LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 398 shares in the last quarter. Quarry LP increased its holdings in LeMaitre Vascular by 267.2% in the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock valued at $64,000 after buying an additional 529 shares in the last quarter. Kestra Advisory Services LLC acquired a new position in shares of LeMaitre Vascular in the fourth quarter worth about $68,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of LeMaitre Vascular during the 4th quarter worth about $80,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.